No Data
CSPC Pharmaceutical Gets US FDA Nod for Metabolism Disease Drug Trial
CSPC PHARMA (01093.HK): JMT202 (recombinant fully human anti-βKLOTHO monoclonal antibody) has received clinical trial approval in the USA.
On May 2, Gelonghui reported that CSPC PHARMA (01093.HK) announced that the restructured fully human anti-β Klotho monoclonal antibody drug JMT202 developed by the group has been approved by the USA Food and Drug Administration (FDA) to conduct clinical research in the USA. This product was also approved by the National Medical Products Administration of China in May 2024 and is currently undergoing clinical trials in China. This product acts as an FGFR1c/β Klotho receptor agonist, specifically activating the FGFR1c/β Klotho receptor complex by binding to the β Klotho protein.
Express News | CSPC Pharmaceutical - Jmt202 Obtains Clinical Trial Approval in U.S.
Express News | Ob Holdings - Letters of Intent Entered Into by Orient Biotech With Units of CSPC Pharmaceutical Group
Express News | CSPC Pharmaceutical - Pivotal Phase II/III Clinical Study of Kn026 Met Primary Endpoint of Progression-Free Survival (Pfs) at Interim Analysis
Hong Kong stocks in motion | CSPC PHARMA rises over 3% as SYH2068 injection (double-stranded small interfering RNA drug) receives clinical trial approval.
CSPC PHARMA (01093) rose over 3%, as of publication, up 3.48%, priced at 6.25 Hong Kong dollars, with a transaction volume of 0.177 billion Hong Kong dollars.
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}